27266-1-AP

antibody from Proteintech Group

Targeting: KMT2D ALR, CAGL114, MLL2, MLL4, TNRC21

ELISA (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

27266-1-AP

Provider

Proteintech Group

Product name

KMT2D antibody

Antibody type

Polyclonal

Description

KD/KO validated KMT2D antibody (Cat. #27266-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

I-FABP protein/mRNA and IL-6 as biomarkers of intestinal barrier dysfunction in neonates with necrotizing enterocolitis and SPF BALB/c mouse models.

Chen J, Yan Z, Lin Z, Fan Y, Bao X, Chen X, Zheng A
The Journal of international medical research 2024 Jun;52(6):3000605241254788

---

The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression.

Liu N, Zhang J, Chen W, Ma W, Wu T
Journal of experimental & clinical cancer research : CR 2023 Oct 11;42(1):263

---

MLL4 Regulates the Progression of Non-Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis.

Yang Y, Qiu R, Weng Q, Xu Z, Song J, Zhao S, Meng M, Zhang D, Kong C, Wang H, Xu M, Zhao Z, Ji J
Cancer research and treatment 2023 Jul;55(3):778-803

---

Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.

Liao X, Li Z, Zheng H, Qian W, Zhang S, Chen S, Li X, Tang M, Xu Y, Yu R, Li M, Song L, Li J
Molecular cancer research : MCR 2023 Jul 5;21(7):648-663

---

Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics Analysis.

Bao X, Li Q, Chen J, Chen D, Ye C, Dai X, Wang Y, Li X, Rong X, Cheng F, Jiang M, Zhu Z, Ding Y, Sun R, Liu C, Huang L, Jin Y, Li B, Lu J, Wu W, Guo Y, Fu W, Langley SR, Tano V, Fang W, Guo T, Sheng J, Zhao P, Ruan J
Cancer immunology research 2022 Jul 1;10(7):811-828

---

Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancer.

Zhai Q, Luo M, Zhang Y, Zhang W, Wu C, Lv S, Wei Q
Translational cancer research 2022 Aug;11(8):2607-2621

---

Histone methyltransferase KMT2D cooperates with MEF2A to promote the stem-like properties of oral squamous cell carcinoma.

Wang X, Li R, Wu L, Chen Y, Liu S, Zhao H, Wang Y, Wang L, Shao Z
Cell & bioscience 2022 Apr 27;12(1):49

---

Pseudogene ACTBP2 increases blood-brain barrier permeability by promoting KHDRBS2 transcription through recruitment of KMT2D/WDR5 in Aβ(1-)(42) microenvironment.

Liu Q, Liu X, Zhao D, Ruan X, Su R, Shang X, Wang D, Yang C, Xue Y
Cell death discovery 2021 Jun 14;7(1):142

---

RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules.

Jiang N, Zhou J, Zhang W, Li P, Liu Y, Shi H, Zhang C, Wang Y, Zhou C, Peng C, Zhang W, Hao Y, Sun Q, Li Y, Zhao X
Thoracic cancer 2021 Jan;12(2):181-193

---

Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.

Leng X, Wang J, An N, Wang X, Sun Y, Chen Z
Oncogene 2020 Oct;39(41):6468-6479

---

KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.

Li SS, Jiang WL, Xiao WQ, Li K, Zhang YF, Guo XY, Dai YQ, Zhao QY, Jiang MJ, Lu ZJ, Wan R
World journal of gastrointestinal oncology 2019 Aug 15;11(8):599-621